CLBIO — Corline Biomedical AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK509.41m
- SEK501.09m
- SEK9.78m
Annual cashflow statement for Corline Biomedical AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.29 | -6.91 | 2.33 | -1.79 | -23.2 |
| Depreciation | |||||
| Non-Cash Items | — | — | — | — | 9.99 |
| Unusual Items | |||||
| Changes in Working Capital | 2.21 | 2.04 | -8.84 | 2.58 | 4.44 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -5.07 | -4.83 | -6.45 | 0.886 | -8.64 |
| Capital Expenditures | -8.8 | -9.62 | -9 | -10.6 | -7.5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 0.056 | 0 | 0 | — |
| Change in Net Investments | |||||
| Cash from Investing Activities | -8.8 | -9.56 | -9 | -10.6 | -7.5 |
| Financing Cash Flow Items | — | -3.51 | — | — | -1.43 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0 | 47.1 | 0.026 | 0.537 | 16.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -13.9 | 32.7 | -15.4 | -9.2 | 0.656 |